GSK (GSK) said Tuesday that the European Commission has approved Exdensur as an add-on maintenance treatment for severe asthma with type 2 inflammation and as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with chronic rhinosinusitis with nasal polyps.

The Commission's approval was based on data from the Swift and Anchor phase 3 trials, in which each of the four trials achieved their primary or co-primary endpoints "with statistically significant and clinically meaningful results," the company said.

Shares of the company were up 2.7% in early Tuesday trading.

Price: 60.54, Change: +1.61, Percent Change: +2.73